<?xml version="1.0" encoding="UTF-8" standalone="yes"?><drugRecordOutput id="57845"><DrugName>high concentration capsaicin (liquid, neuropathic pain), NeurogesX</DrugName><DrugNamesKey><Name id="42755807">capsaicin</Name></DrugNamesKey><DrugSynonyms><Name><Value>capsaicin</Value><Types><Type>PINN</Type></Types></Name><Name><Value>high concentration capsaicin (liquid, neuropathic pain), NeurogesX</Value></Name><Name><Value>NGX-1998</Value><Types><Type>Research Code</Type></Types></Name><Name><Value>NP-1998</Value><Types><Type>Research Code</Type></Types></Name><Name><Value>404-86-4</Value><Types><Type>CAS RN</Type></Types></Name></DrugSynonyms><CompanyOriginator id="28832">NeurogesX Inc</CompanyOriginator><CompaniesSecondary><Company id="24347">Acorda Therapeutics Inc</Company><Company id="28832">NeurogesX Inc</Company></CompaniesSecondary><CrossReferences><SourceEntity id="24347" type="Company"><TargetEntity id="4295909042" type="organizationId">Acorda Therapeutics Inc</TargetEntity></SourceEntity><SourceEntity id="28832" type="Company"><TargetEntity id="4295906287" type="organizationId">NeurogesX Inc</TargetEntity></SourceEntity><SourceEntity id="101" type="ciIndication"><TargetEntity id="10012680" type="MEDDRA"></TargetEntity><TargetEntity id="D003929" type="MeSH"></TargetEntity><TargetEntity id="-1144631334" type="omicsDisease"></TargetEntity><TargetEntity id="169" type="siCondition"></TargetEntity></SourceEntity><SourceEntity id="1295" type="ciIndication"><TargetEntity id="10029223" type="MEDDRA"></TargetEntity><TargetEntity id="D009437" type="MeSH"></TargetEntity><TargetEntity id="-533466818" type="omicsDisease"></TargetEntity><TargetEntity id="14" type="siCondition"></TargetEntity></SourceEntity><SourceEntity id="3300" type="ciIndication"><TargetEntity id="10036376" type="MEDDRA"></TargetEntity><TargetEntity id="D051474" type="MeSH"></TargetEntity><TargetEntity id="-1650985330" type="omicsDisease"></TargetEntity><TargetEntity id="17" type="siCondition"></TargetEntity></SourceEntity><SourceEntity id="PTGT-01927" type="ciTarget"><TargetEntity id="103809874423" type="siTarget">Transient receptor potential cation channel subfamily V member 1</TargetEntity><TargetEntity id="907" type="omicsTarget"></TargetEntity></SourceEntity></CrossReferences><PhaseHighest id="DX">Discontinued</PhaseHighest><PhaseTerminated id="C2">Phase 2 Clinical</PhaseTerminated><IndicationsSecondary><Indication id="101">Diabetic neuropathy</Indication><Indication id="1295">Neuropathic pain</Indication><Indication id="3300">Postherpetic neuralgia</Indication></IndicationsSecondary><ActionsPrimary><Action id="6937">Vanilloid VR1 agonist</Action></ActionsPrimary><ActionsSecondary><Action id="2946">Analgesic</Action></ActionsSecondary><Technologies><Technology id="744">Liquid-based formulation technology</Technology><Technology id="558">Transdermal formulation</Technology><Technology id="762">Small molecule therapeutic</Technology></Technologies><EphmraCodes><Ephmra><Code>N2</Code><Name>ANALGESICS</Name></Ephmra></EphmraCodes><LastModificationDate>2018-03-29T18:23:24.000Z</LastModificationDate><ChangeDateLast>2018-08-14T00:00:00.000Z</ChangeDateLast><AddedDate>2007-08-09T14:17:31.000Z</AddedDate><DevelopmentProfile><Summary><displayLabel>Summary</displayLabel><value>&lt;Summary&gt;&lt;para&gt;&lt;ulink linkID="24347" linkType="Company"&gt;Acorda&lt;/ulink&gt;, from a drug acquisition from &lt;ulink linkID="28832" linkType="Company"&gt;NeurogesX&lt;/ulink&gt;, was developing NGX-1998 (NP-1998), a high-concentration  topical liquid formulation of the capsaicin used in &lt;ulink linkID="39893" linkType="Drug"&gt;NGX-4010&lt;/ulink&gt;, for the potential treatment of neuropathic pain [&lt;ulink linkID="1450081" linkType="Reference"&gt;1450081&lt;/ulink&gt;].  In  October 2010,  NeurogesX initiated a phase II trial   [&lt;ulink linkID="1144171" linkType="Reference"&gt;1144171&lt;/ulink&gt;], [&lt;ulink linkID="1143881" linkType="Reference"&gt;1143881&lt;/ulink&gt;];  positive data were presented in August 2012  [&lt;ulink linkID="1319299" linkType="Reference"&gt;1319299&lt;/ulink&gt;]. In July 2013, the agent was described as phase III ready and Acorda was to further develop it for neuropathic pain, with an initial emphasis on painful diabetic neuropathy [&lt;ulink linkID="1450081" linkType="Reference"&gt;1450081&lt;/ulink&gt;]; in January 2015, the company decided not to pursue the development of the drug for neuropathic pain in 2015 [&lt;ulink linkID="1626128" linkType="Reference"&gt;1626128&lt;/ulink&gt;]; in March 2015, the drug was no longer listed on the company's development pipeline [&lt;ulink linkID="1637912" linkType="Reference"&gt;1637912&lt;/ulink&gt;]. In March 2018, Acorda was seeking to oulicense or partner NGX-1998 [&lt;ulink linkID="2010264" linkType="Reference"&gt;2010264&lt;/ulink&gt;]. &lt;/para&gt;&lt;para&gt;NeurogesX was previously developing the agent for neuropathic pain including post-herpetic neuralgia (PHN) [&lt;ulink linkID="821060" linkType="Reference"&gt;821060&lt;/ulink&gt;], [&lt;ulink linkID="1032239" linkType="Reference"&gt;1032239&lt;/ulink&gt;], [&lt;ulink linkID="1143881" linkType="Reference"&gt;1143881&lt;/ulink&gt;].   In  October 2010,  NeurogesX initiated a phase II trial in PHN patients   [&lt;ulink linkID="1144171" linkType="Reference"&gt;1144171&lt;/ulink&gt;], [&lt;ulink linkID="1143881" linkType="Reference"&gt;1143881&lt;/ulink&gt;].  By August 2007, the company had conducted a  phase I neuropathic pain trial [&lt;ulink linkID="821060" linkType="Reference"&gt;821060&lt;/ulink&gt;]. In May 2009, phase II trials for neuropathic pain were dependent on the company finding additional funding and at that time, the company was evaluating the timing of entering phase II development [&lt;ulink linkID="1007544" linkType="Reference"&gt;1007544&lt;/ulink&gt;], [&lt;ulink linkID="1019998" linkType="Reference"&gt;1019998&lt;/ulink&gt;]. In August 2012,    NeurogesX  received end-of-phase II  guidance from the FDA regarding its previously announced plans for the phase III  development of NGX-1998 including   trial design, manufacturing plans and applicator development [&lt;ulink linkID="1313784" linkType="Reference"&gt;1313784&lt;/ulink&gt;]. In November 2012, patient enrollment in a phase III trial was expected to begin in first quarter of 2013 [&lt;ulink linkID="1340916" linkType="Reference"&gt;1340916&lt;/ulink&gt;]. In November 2011, NeurogesX was seeking to outlicense the drug [&lt;ulink linkID="1237505" linkType="Reference"&gt;1237505&lt;/ulink&gt;]; however,  the drug was acquired by Acorda in the US, Canada, Latin America and certain other territories in July 2013 [&lt;ulink linkID="1450081" linkType="Reference"&gt;1450081&lt;/ulink&gt;], [&lt;ulink linkID="1524731" linkType="Reference"&gt;1524731&lt;/ulink&gt;].&lt;/para&gt;&lt;/Summary&gt;</value></Summary><Premarketing><displayLabel>Premarketing</displayLabel><value>&lt;Premarketing&gt;&lt;para&gt;In November 2011, an end-of-phase II meeting with the FDA was expected in the first half of 2012 [&lt;ulink linkID="1237505" linkType="Reference"&gt;1237505&lt;/ulink&gt;]. In March 2012, the company planned for a phase III  trial by the end of 2012 [&lt;ulink linkID="1270068" linkType="Reference"&gt;1270068&lt;/ulink&gt;]. In April 2012, the company reported that the FDA had accepted the request for an end-of-phase II meeting to discuss on the  company's plans to enter phase III development. At that time, the meeting was expected in the third quarter of 2012 [&lt;ulink linkID="1279379" linkType="Reference"&gt;1279379&lt;/ulink&gt;]. In June 2012, the company intended to discuss  a 505 (b) (2) clinical development program at the end-of-phase II meeting [&lt;ulink linkID="1302312" linkType="Reference"&gt;1302312&lt;/ulink&gt;]. In July 2012, a phase III trial was expected to begin by the end of that year [&lt;ulink linkID="1308809" linkType="Reference"&gt;1308809&lt;/ulink&gt;]; by August 2012, the company had submitted a briefing package to the FDA for the meeting [&lt;ulink linkID="1313096" linkType="Reference"&gt;1313096&lt;/ulink&gt;]; later that month, NeurogesX  received end-of-phase II  guidance from the FDA regarding its previously announced plans for the phase III  development of NGX-1998 including   trial design, manufacturing plans and applicator development [&lt;ulink linkID="1313784" linkType="Reference"&gt;1313784&lt;/ulink&gt;]; in November 2012, the trial was expected to enroll patients in the first quarter of 2013 [&lt;ulink linkID="1340916" linkType="Reference"&gt;1340916&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;In May 2010, a phase II trial for post-herpetic neuralgia (PHN) was planned [&lt;ulink linkID="1098586" linkType="Reference"&gt;1098586&lt;/ulink&gt;]. In October 2010, the  multicenter, randomized, double-blind, placebo-controlled, adaptive-design,  safety, efficacy and tolerability, two stage phase II study (&lt;ulink linkID="71702" linkType="Protocol"&gt;NCT01228838&lt;/ulink&gt;; C204)   was initiated  in PHN patients (expected n = 200) in the US. At that time, the trial was expected to complete in December 2011. In November 2010, the first patient was dosed [&lt;ulink linkID="1144171" linkType="Reference"&gt;1144171&lt;/ulink&gt;], [&lt;ulink linkID="1143881" linkType="Reference"&gt;1143881&lt;/ulink&gt;]. In May 2011, the trial was ongoing and enrollment had passed 65% [&lt;ulink linkID="1187279" linkType="Reference"&gt;1187279&lt;/ulink&gt;]; in June 2011, enrollment (n = 183) was completed. The first stage trial results showed that no topical anesthetic was  needed to attain  the  trial's tolerability goal, and top-line data were expected by the end 2011 [&lt;ulink linkID="1200610" linkType="Reference"&gt;1200610&lt;/ulink&gt;]. By June 2011, patient dosing in the second stage of the trial had been completed, using no pretreatment regimen and a 5-minute application [&lt;ulink linkID="1213707" linkType="Reference"&gt;1213707&lt;/ulink&gt;], [&lt;ulink linkID="1235171" linkType="Reference"&gt;1235171&lt;/ulink&gt;]. In November 2011, topline results were reported showing that the study met the primary endpoint of change from baseline in patient-reported numeric pain rating scale score from week 2 to 8 compared with placebo. NGX-1998 showed a dose-response and the reduction in pain scores was maintained over 12 weeks [&lt;ulink linkID="1237505" linkType="Reference"&gt;1237505&lt;/ulink&gt;]. In May 2012, similar data were presented at the 31st Annual APS Meeting in Honolulu, HI [&lt;ulink linkID="1285714" linkType="Reference"&gt;1285714&lt;/ulink&gt;]. In July 2012, data from the 184-patient, proof-of-concept trial were expected to be presented at the 14th World Congress on Pain in Milan, Italy in August 2012 [&lt;ulink linkID="1308809" linkType="Reference"&gt;1308809&lt;/ulink&gt;]. In August 2012, data were presented. Data demonstrated that NGX-1998 was well tolerated. NGX-1998 showed a greater magnitude of response on the pain intensity scale correlating with the concentration of the formulation (20% &amp;gt; 10% &amp;gt; placebo) [&lt;ulink linkID="1319299" linkType="Reference"&gt;1319299&lt;/ulink&gt;]. &lt;/para&gt;&lt;para&gt;By August 2012, four phase I trials have been completed [&lt;ulink linkID="1319299" linkType="Reference"&gt;1319299&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;By March 2009, three phase I trials had been completed [&lt;ulink linkID="993091" linkType="Reference"&gt;993091&lt;/ulink&gt;]. &lt;/para&gt;&lt;para&gt;In June 2008, the company filed an IND. At that time, the company planned to begin a phase I trial for peripheral neuropathic pain later in 2008 [&lt;ulink linkID="912666" linkType="Reference"&gt;912666&lt;/ulink&gt;]. A phase I trial began in July 2008. The randomized, single-blind trial (study C203) would test various formulations of the drug for use in future clinical trials and was scheduled for completion by the end of that year [&lt;ulink linkID="924478" linkType="Reference"&gt;924478&lt;/ulink&gt;]. By November 2008, enrollment had been completed [&lt;ulink linkID="960082" linkType="Reference"&gt;960082&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;By July 2008, two phase I trials had been completed under an exploratory IND [&lt;ulink linkID="924478" linkType="Reference"&gt;924478&lt;/ulink&gt;]. &lt;/para&gt;&lt;para&gt;By April 2006, the company had initiated an exploratory IND  for NGX-1998 [&lt;ulink linkID="821060" linkType="Reference"&gt;821060&lt;/ulink&gt;]. By August 2007, the company had conducted a phase I trial in 30 healthy volunteers under the exploratory IND. A 5 min application of NGX-1998 directly to the skin produced a similar reduction in epidermal nerve fiber density to a 60 min application of NGX-4010 and was associated with less discomfort [&lt;ulink linkID="820845" linkType="Reference"&gt;820845&lt;/ulink&gt;].&lt;/para&gt;&lt;/Premarketing&gt;</value></Premarketing><AdditionalInformation><displayLabel>Additional Information</displayLabel><value>&lt;AdditionalInformation&gt;&lt;para&gt;&lt;/para&gt;&lt;para&gt;In May 2009, phase II trials were dependent on the company finding additional funding [&lt;ulink linkID="1007544" linkType="Reference"&gt;1007544&lt;/ulink&gt;]; in May 2009, the company had secured funding through an option for license of the drug to &lt;ulink linkID="20972" linkType="Company"&gt;Astellas Pharma Europe&lt;/ulink&gt;, and as such NeurogesX was evaluating the timing of entering phase II development [&lt;ulink linkID="1019998" linkType="Reference"&gt;1019998&lt;/ulink&gt;].&lt;/para&gt;&lt;/AdditionalInformation&gt;</value></AdditionalInformation></DevelopmentProfile><IDdbDevelopmentStatus><DevelopmentStatusCurrent><Company id="28832">NeurogesX Inc</Company><Country id="US">US</Country><DevelopmentStatus id="DX" sortOrder="4">Discontinued</DevelopmentStatus><DiscontinuedReason id="5">Other</DiscontinuedReason><Indication id="1295">Neuropathic pain</Indication><StatusDate>2013-07-09T00:00:00.000Z</StatusDate><Source id="1450081" type="PR"/></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="28832">NeurogesX Inc</Company><Country id="US">US</Country><DevelopmentStatus id="DX" sortOrder="4">Discontinued</DevelopmentStatus><DiscontinuedReason id="5">Other</DiscontinuedReason><Indication id="3300">Postherpetic neuralgia</Indication><StatusDate>2013-07-09T00:00:00.000Z</StatusDate><Source id="1450081" type="PR"/></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="24347">Acorda Therapeutics Inc</Company><Country id="US">US</Country><DevelopmentStatus id="NDR" sortOrder="3">No Development Reported</DevelopmentStatus><Indication id="1295">Neuropathic pain</Indication><StatusDate>2015-03-03T00:00:00.000Z</StatusDate></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="24347">Acorda Therapeutics Inc</Company><Country id="US">US</Country><DevelopmentStatus id="NDR" sortOrder="3">No Development Reported</DevelopmentStatus><Indication id="101">Diabetic neuropathy</Indication><StatusDate>2015-03-03T00:00:00.000Z</StatusDate></DevelopmentStatusCurrent><DevelopmentStatusHistoric><Company id="28832">NeurogesX Inc</Company><Country id="US">US</Country><DevelopmentStatus id="C1" sortOrder="10">Phase 1 Clinical</DevelopmentStatus><Indication id="1295">Neuropathic pain</Indication><StatusDate>2006-04-30T00:00:00.000Z</StatusDate><Source id="821060" type="CORPORATE"/></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="28832">NeurogesX Inc</Company><Country id="US">US</Country><DevelopmentStatus id="C2" sortOrder="11">Phase 2 Clinical</DevelopmentStatus><Indication id="3300">Postherpetic neuralgia</Indication><StatusDate>2010-10-31T00:00:00.000Z</StatusDate><Source id="1144171" type="TRIALREG"/></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="24347">Acorda Therapeutics Inc</Company><Country id="US">US</Country><DevelopmentStatus id="C2" sortOrder="11">Phase 2 Clinical</DevelopmentStatus><Indication id="1295">Neuropathic pain</Indication><StatusDate>2013-07-09T00:00:00.000Z</StatusDate><Source id="1450081" type="PR"/></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="24347">Acorda Therapeutics Inc</Company><Country id="US">US</Country><DevelopmentStatus id="DR" sortOrder="7">Discovery</DevelopmentStatus><Indication id="101">Diabetic neuropathy</Indication><StatusDate>2013-07-09T00:00:00.000Z</StatusDate><Source id="1450081" type="PR"/></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="24347">Acorda Therapeutics Inc</Company><Country id="US">US</Country><DevelopmentStatus id="S" sortOrder="6">Suspended</DevelopmentStatus><Indication id="1295">Neuropathic pain</Indication><StatusDate>2015-01-12T00:00:00.000Z</StatusDate><Source id="1626128" type="PR"/></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="28832">NeurogesX Inc</Company><Country id="US">US</Country><DevelopmentStatus id="DR" sortOrder="7">Discovery</DevelopmentStatus><Indication id="1295">Neuropathic pain</Indication><StatusDate>2006-04-30T00:00:00.000Z</StatusDate><Source id="821060" type="CORPORATE"/></DevelopmentStatusHistoric></IDdbDevelopmentStatus><Targets><Target id="PTGT-01927"><Name>Vanilloid VR1 receptor</Name><SwissprotNumbers><Swissprot>O35433</Swissprot><Swissprot>Q697L1</Swissprot><Swissprot>Q6R5A3</Swissprot><Swissprot>Q6RX08</Swissprot><Swissprot>Q704Y3</Swissprot><Swissprot>Q8NER1</Swissprot></SwissprotNumbers></Target></Targets><ReasonsForUpdate><ReasonForUpdate><Reason>Development Status Updated</Reason><Description>One or more development status entries have been updated</Description></ReasonForUpdate></ReasonsForUpdate><CountsByCompanies><Company><Company id="1013295">Astellas Pharma Inc</Company><CountAsPrincipalActive>1</CountAsPrincipalActive><CountAsPrincipalInactive>0</CountAsPrincipalInactive><CountAsPartnerActive>1</CountAsPartnerActive><CountAsPartnerInactive>0</CountAsPartnerInactive><CountTotal>1</CountTotal></Company><Company><Company id="20547">University of California</Company><CountAsPrincipalActive>0</CountAsPrincipalActive><CountAsPrincipalInactive>0</CountAsPrincipalInactive><CountAsPartnerActive>0</CountAsPartnerActive><CountAsPartnerInactive>0</CountAsPartnerInactive><CountTotal>1</CountTotal></Company><Company><Company id="24347">Acorda Therapeutics Inc</Company><CountAsPrincipalActive>1</CountAsPrincipalActive><CountAsPrincipalInactive>0</CountAsPrincipalInactive><CountAsPartnerActive>1</CountAsPartnerActive><CountAsPartnerInactive>0</CountAsPartnerInactive><CountTotal>1</CountTotal></Company><Company><Company id="28832">NeurogesX Inc</Company><CountAsPrincipalActive>1</CountAsPrincipalActive><CountAsPrincipalInactive>0</CountAsPrincipalInactive><CountAsPartnerActive>1</CountAsPartnerActive><CountAsPartnerInactive>0</CountAsPartnerInactive><CountTotal>3</CountTotal></Company></CountsByCompanies><CountsByTypes><Type><Type sortOrder="14">Drug - Asset Divestment</Type><CountActive>1</CountActive><CountInactive>0</CountInactive><CountTotal>1</CountTotal></Type><Type><Type sortOrder="3">Drug - Early Research/Development</Type><CountActive>1</CountActive><CountInactive>0</CountInactive><CountTotal>1</CountTotal></Type><Type><Type sortOrder="4">Drug - Development/Commercialization License</Type><CountActive>1</CountActive><CountInactive>0</CountInactive><CountTotal>1</CountTotal></Type></CountsByTypes><StructureSmiles><Smiles>CC(C)/C=C/CCCCC(=O)NCc1ccc(c(c1)OC)O</Smiles></StructureSmiles><Deals><Deal id="126130" title="Astellas Pharma Europe to market NeurogesX's NGX-4010 in the European Economic Area, the Middle East and Africa  "/><Deal id="145821" title="Acorda to acquire NeurogesX' NGX-4010 and NGX-1998 for neuropathic pain in the US, Canada, Latin America and certain other territories  "/><Deal id="172037" title="UCSF to develop NeurogesX' high dose capsaicin for neuropathic pain "/></Deals><PatentFamilies><PatentFamily id="1383770" number="WO-2004091521" title="Methods and compositions for administration of TRPV1 agonists"/><PatentFamily id="873962" number="WO-2006107723" title="Oils of capsaicinoids and methods of making and using the same"/></PatentFamilies><PatentFamilyCountsByTypes><PatentFamilyCountsByType><Type sortorder="12">Product</Type><Count>1</Count></PatentFamilyCountsByType><PatentFamilyCountsByType><Type sortorder="14">Tentative</Type><Count>1</Count></PatentFamilyCountsByType></PatentFamilyCountsByTypes><PatentFamilyCountsByCompanies><PatentFamilyCountsByCompany><CompanyLink nameDisplay="Acorda Therapeutics Inc" id="24347"/><CountAsOwner>1</CountAsOwner><CountAsThirdParty>0</CountAsThirdParty><CountTotal>1</CountTotal></PatentFamilyCountsByCompany><PatentFamilyCountsByCompany><CompanyLink nameDisplay="NeurogesX Inc" id="28832"/><CountAsOwner>2</CountAsOwner><CountAsThirdParty>0</CountAsThirdParty><CountTotal>2</CountTotal></PatentFamilyCountsByCompany></PatentFamilyCountsByCompanies><hasSWOTs>N</hasSWOTs></drugRecordOutput>